Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

cancernetwork.com image

News from cancernetwork.com

See all of cancernetwork.com news coverage in one place. Discover how cancernetwork.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 691 headlines reported on by cancernetwork.com during the past 3 months.

Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about cancernetwork.com

Where is cancernetwork.com located?cancernetwork.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top cancernetwork.com News

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

Johnson & Johnson · United States

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

71% Center coverage: 32 sources

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story

New Bispecific T-Cell Engager Approved for Multiple Myeloma

Cancer · United States

New Bispecific T-Cell Engager Approved for Multiple Myeloma

83% Center coverage: 6 sources

(MedPage Today) -- The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy. A B-cell maturation antigen (BCMA)-directed bispecific antibody...See the Story

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

67% Right coverage: 3 sources

/PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European...See the Story

Liquid Biopsy in Breast Cancer: Clinical Implications of ctDNA and CTCs in Diagnosis, Treatment, and Monitoring

The authors focus on the clinical applications of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in breast cancer progression, relapse, diagnosis, and treatment response. [Molecular and Cellular Biochemistry] AbstractCancer See the Story

FDA Loosens Restrictions on First-Gen CAR-T Therapies

100% Center coverage: 2 sources

There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.Cancer · United States See the Story

Current Use and Future Directions of Artificial Intelligence in Hematology/Oncology

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.Artificial Intelligence Read Article

Advances in NSCLC Bring Excitement in the Lung Space

According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.Maryland · Maryland Read Article

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.Read Article

Diagnosing and Treating Patients With Epithelioid Sarcoma

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.United States · United States Read Article

Expert Opinion on Modern Availability of Several Agents

Panelists discuss how the availability of multiple B-cell maturation antigen (BCMA) bispecific agents (with linvoseltamab approved in Europe and other agents in development) creates beneficial competition that could drive down costs and provide more treatment options, while acknowledging that safety and efficacy profiles appear comparable across agents, making accessibility and convenience key differentiating factors for patient care.Read Article

Data Review of Teclistamab and Elranatamab in R/R MM

Panelists discuss how recent long-term follow-up data for teclistamab and elranatamab reaffirm their effectiveness in relapsed/refractory multiple myeloma (R/R MM) with no new safety signals, while emphasizing that direct comparisons between B-cell maturation antigen (BCMA) bispecifics may not be fair due to evolving mitigation strategies, improved supportive care practices, and different study conditions including the impact of COVID-19 on earl…Read Article

Breaking News Topics Related to cancernetwork.com